9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen

Condition Non-small Cell Lung Cancer|Mesothelioma|Lung Neoplasms Estimated Enrollment: 31 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 10426|H3E-MC-JMHX Study First Received: April 18, 2006 Last Updated: June 10, 2010 Estimated Primary Completion Date: March 2009 Primary Outcome Measures: Overview of Adverse Events|Number of Participants With Common Toxicity Criteria - National Cancer Institute Grade 3 and Grade 4 Toxicities|Pemetrexed Population Pharmacokinetics (PK): Clearance|Pemetrexed Population Pharmacokinetics: Volume of Distribution|Discontinuations Due to Adverse Events Sponsors and Collaborators: Eli Lilly and Company Result Received: March 10, 2010 Website Link: https://ClinicalTrials.gov/show/NCT00316225...

Continue reading

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma

Condition Advanced Malignant Mesothelioma|Epithelial Mesothelioma|Localized Malignant Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatous Mesothelioma Estimated Enrollment: 106 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment Study ID Numbers: NCI-2012-02430|CDR0000069058|NCI-2710|UCCRC-11046A|11046A|2710|N01CM17102|P30CA014599 Study First Received: December 7, 2001 Last Updated: February 10, 2014 Estimated Primary Completion Date: May 2006 Primary Outcome Measures: Time to disease progression|Complete response rate|Objective response rate (complete and partial response)|Rate of disease stabilization|Overall survival|Incidence of adverse events graded according to NCI CTCAE version 3.0 Sponsors and Collaborators: National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00027703...

Continue reading

A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer

Condition Pancreatic Cancer|Mesothelioma|Ovarian Cancer|Non-Small Cell Lung Cancer Estimated Enrollment: 24 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: MORAb-009-001 Study First Received: May 11, 2006 Last Updated: July 16, 2014 Estimated Primary Completion Date: September 2008 Primary Outcome Measures: Safety and Tolerability as a measure of Adverse Events/Serious Adverse Events|Safety and Tolerability as a measure of clinical laboratory parameters|Safety and Tolerability as a measure of physical examinations, vital signs, and ECGs|Pharmacokinetics of MORAb-009|Percentage of Participants With Antibodies Against Infliximab (Human Anti-chimeric Antibody [HACA])|Objective Tumor Response Rate Assessed by Investigator Sponsors and...

Continue reading

Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma

Condition Pleural Neoplasms Estimated Enrollment: 77 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 7216|H3E-US-JMGA Study First Received: July 12, 2004 Last Updated: May 1, 2009 Estimated Primary Completion Date: February 2008 Primary Outcome Measures: Pathological Complete Response|The 1 and 2 Year Disease-Free Survival Rate (Percentage)|Overall Tumor Response|Time to Treatment Failure|Time to Progressive Disease|Overall Survival Time Sponsors and Collaborators: Eli Lilly and Company Result Received: February 16, 2009 Website Link: https://ClinicalTrials.gov/show/NCT00087698...

Continue reading

Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura

Condition Esophageal Cancer|Lung Cancer|Malignant Mesothelioma|Metastatic Cancer Estimated Enrollment: null Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Primary Purpose: Treatment Study ID Numbers: CDR0000067228|NCI-99-C-0129|NCI-T99-0012 Study First Received: July 11, 2001 Last Updated: April 28, 2015 Estimated Primary Completion Date: null Primary Outcome Measures: Sponsors and Collaborators: National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00019825...

Continue reading

Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.

Condition Epithelial Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatous Mesothelioma|Stage IA Malignant Mesothelioma|Stage IB Malignant Mesothelioma|Stage II Malignant Mesothelioma|Stage III Malignant Mesothelioma|Stage IV Malignant Mesothelioma Estimated Enrollment: 44 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: NCI-2012-02813|CALGB-30307|CDR0000415372|U10CA031946 Study First Received: April 5, 2005 Last Updated: June 4, 2013 Estimated Primary Completion Date: June 2007 Primary Outcome Measures: Response rate (including complete and partial response)|Time to tumor progression|Percentage of patients remaining failure-free|Overall survival Sponsors and Collaborators: National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00107432...

Continue reading

Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma

Condition Malignant Pleural Mesotherioma Estimated Enrollment: 12 Age Group: 20 Years to 75 Years   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 5249|H3E-JE-ME01 Study First Received: November 8, 2005 Last Updated: November 5, 2007 Estimated Primary Completion Date: null Primary Outcome Measures: To determine the recommended dose of LY231514 and cisplatin combination therapy, Response Rate|Duration of response|Progression free survival|Median survival time|1 year survival rate|Pulmonary function|QOL|Safety|Plasma concentration Sponsors and Collaborators: Eli Lilly and Company Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00251550...

Continue reading

Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas

Condition Lung Cancer|Esophageal Cancer|Malignant Pleural Mesothelioma|Sarcoma|Thymic Carcinoma Estimated Enrollment: 10 Age Group: 18 Years to 120 Years   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Primary Purpose: Treatment Study ID Numbers: 100138|10-C-0138 Study First Received: June 11, 2010 Last Updated: April 20, 2017 Estimated Primary Completion Date: February 9, 2015 Primary Outcome Measures: Tabulation of toxicity type and grade|To ascertain if K526-GM vaccines induce immunity to CT antigens commonly expressed in thoracic malignancies.|To determine if metronomic oral CP and celecoxib reduce the number, percentage and function of CD4+ CD25+ Fox P3+ regulatory T cells (T reg) in peripheral blood of thoracic oncology patients. Sponsors and Collaborators: National...

Continue reading

Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma

Condition Carcinoma, Non-Small-Cell Lung|Mesothelioma Estimated Enrollment: 18 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: CLBH589B2109 Study First Received: September 26, 2007 Last Updated: November 26, 2012 Estimated Primary Completion Date: January 2009 Primary Outcome Measures: Pharmacokinetic (PK) parameters|Response rate assessed by comparing tumor size via radiology scans (CTs or MRIs)|Safety (until disease progression, unacceptable toxicity or study completion) assessed by duration of patient participation|Tolerability (until disease progression, unacceptable toxicity or study completion) assessed by duration of patient participation Sponsors and Collaborators: Novartis Pharmaceuticals|Novartis Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00535951...

Continue reading

MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC

Condition Malignant Pleural Mesothelioma|Non-Small Cell Lung Cancer Estimated Enrollment: 27 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment Study ID Numbers: HREC/13/CRGH/199 Study First Received: January 5, 2015 Last Updated: April 5, 2017 Estimated Primary Completion Date: January 4, 2017 Primary Outcome Measures: There is a composite primary outcome to establish maximum tolerated dose and dose limiting toxicities The MTD will be determined by the assessment of dose limiting toxicities.|to evaluate the effect of multiple dosing of TargomiRs|to detect early signs of efficacy|QOL assessment|ECOG PS change|Pulmonary function change Sponsors and Collaborators: Asbestos Diseases Research Foundation|EnGeneIC Limited Result...

Continue reading